FDA approves interchangeable ranibizumab biosimilar from Coherus BioSciences

The U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.

This week in retina: August 6-August 12

An end-of-week review of retina news and stories from August 6-August 12.

EURETINA 2022: Stepping into the future of ophthalmology

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.